P-025: Investigating the effect of irreversible proteasome inhibitor carfilzomib in in vivo models of cardiometabolic syndrome and early stage HFrEFP: prophylactic role of metformin — Panagiotis Efentakis (2022) | RDL Network
P-025: Investigating the effect of irreversible proteasome inhibitor carfilzomib in in vivo models of cardiometabolic syndrome and early stage HFrEFP: prophylactic role of metformin
Panagiotis Efentakis, Sofia Lamprou, Aimilia Varela, Papanagnou Eleni-Dimitra, Andriana Christodoulou, Maria Gavriatopoulou, Constantinos H. Davos, Ioannis Trougkakos, Meletios A Dimopoulos, Evangelos Terpos, Ioanna Andreadou
Panagiotis Efentakis, Hendrik Doerschmann, Claudius Witzler, Svenja Siemer, Panagiota Nikolaou, Efstathios Kastritis, Roland H. Stauber, Meletios A Dimopoulos, Philip Wenzel, Ioanna Andreadou, Evangelos Terpos
Panagiotis Efentakis, Aimilia Varela, Sofia Lamprou, Eleni‐Dimitra Papanagnou, Michail Chatzistefanou, Andriana Christodoulou, Constantinos H. Davos, Maria Gavriatopoulou, Ioannis P. Trougakos, Meletios A Dimopoulos, Evangelos Terpos, Ioanna Andreadou
Discussion(0)
No comments yet. Be the first to comment.